Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25

Showing 25 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy
Jiwoong Choi, Byeongmin Park, Jung Yeon Park, et al.
Advanced Materials (2024) Vol. 36, Iss. 38
Closed Access | Times Cited: 12
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
Rong Wang, Shiwei He, Jun Long, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Xiaohui Ren, Lijuan Wang, Likun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
Novel dual-targeting PROTAC degraders of GSK-3β and CDK5: A promising approach for pancreatic cancer treatment
Neerasa Jayaprakash, Byeonggwan Kim, Hye Jin Chung
Bioorganic & Medicinal Chemistry (2025) Vol. 120, pp. 118085-118085
Closed Access
Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
Claudia Cerella, Mario Dicato, Marc Diederich
Pharmacological Research (2023) Vol. 196, pp. 106914-106914
Open Access | Times Cited: 12
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy
Soon-Bin Kim, Soonjae Hwang, Ji-Young Cha, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2939-2939
Open Access | Times Cited: 2
New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer
Zhi Li, Xi Yu, Zeting Yuan, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189152-189152
Closed Access | Times Cited: 2
The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy
Xuemei Wang, Ying Zhang, Yao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Deciphering roles of protein post-translational modifications in IgA nephropathy progression and potential therapy
Meng‐Ying Sun, Guojuan Shi, Xiaohan Zhang, et al.
Aging (2024)
Open Access | Times Cited: 1
The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors
Minyu Kong, Yu Xiao, Wenzhi Guo, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 15, pp. 4834-4848
Open Access | Times Cited: 4
Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases
Ao Wang, Yi Zhang, Xinting Lv, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 8, pp. 3295-3311
Open Access | Times Cited: 1
Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy
Zhimin Zhang, Liubin Guo, Mengting Zhao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18682-18698
Closed Access | Times Cited: 1
Novel Pyrido[3,2-d]pyrimidines as HPK1 Inhibitors for Treating Cancer and Inflammatory and Autoimmune Diseases
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 12, pp. 1627-1628
Open Access | Times Cited: 2
Novel Tetrahydropyrido[3,4-d]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 3, pp. 318-319
Closed Access
Unraveling role of ubiquitination in drug resistance of gynecological cancer
Yu Li
American Journal of Cancer Research (2024) Vol. 14, Iss. 5, pp. 2523-2537
Open Access
Bcl-Xl is Translocated to the Nucleus Via Ctbp2 to Epigenetically Promote Metastasis
Tiantian Zhang, Sha Li, Yingcai Adrian Tan, et al.
(2024)
Open Access
PROTAC<sup>®</sup> technology and potential for its application in infection control
M. A. Zakharova, М. В. Чудинов
Fine Chemical Technologies (2024) Vol. 19, Iss. 3, pp. 214-231
Open Access
Immunotherapeutic strategies in hepatopancreatobiliary cancers
Massimiliano Salati, Alessandro Rizzo, Angela Dalia Ricci, et al.
Elsevier eBooks (2024), pp. 103-124
Closed Access
Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis
Tiantian Zhang, Sha Li, Yingcai Adrian Tan, et al.
Cancer Letters (2024) Vol. 604, pp. 217240-217240
Closed Access
Fragment-based approaches to discover ligands for tumor-specific E3 ligases
Junhyeong Yim, S S Kim, Hyung Ho Lee, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-14
Closed Access
Opportunities and challenges for targeting HPK1 in cancer immunotherapy
Jiamei Xu, Ying‐Zhou Li, Xinyi Chen, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107866-107866
Closed Access
Liposomes-mediated enhanced antitumor effect of docetaxel with BRD4-PROTAC as synergist for breast cancer chemotherapy/immunotherapy
Xixi Chen, Fang Li, Baoxia Cui, et al.
International Journal of Pharmaceutics (2024), pp. 124973-124973
Closed Access
Page 1

Scroll to top